☆ 4.7 Review

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy

BIOMEDICINES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer

Qing Zhou et al.

Summary: This study investigated whether PD-L1 expression in CTCs could be a predictive biomarker for immunotherapy efficacy in advanced NSCLC patients. PD-L1 expression in CTCs was higher than in tumor tissues, but there was no correlation between them. Patients with PD-L1 expression on tissue or CTCs had longer mPFS and could potentially benefit from immunotherapy.

THORACIC CANCER (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy

Zaigang Zhou et al.

Summary: Recently, it was discovered that the highly expressed PD-L1 in tumor cells significantly impairs the DNA damage induced by Cis-Pt chemotherapy. Additionally, severe side effects of Cis-Pt, such as enhanced drug efflux caused by MDR-1 and increased tumor metastasis, limit its efficacy. However, a new finding shows that Ch-Met has selective mitochondria accumulation capacity, disrupting mitochondrial function and effectively inhibiting upregulated PD-L1 expression, DNA damage repair, drug efflux, and tumor metastasis. This suggests that Ch-Met can enhance the chemotherapy efficacy of Cis-Pt.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2023)

添加到收藏夹

Article Oncology

Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab

Maria Spiliotaki et al.

Summary: This study investigated the expression of programmed cell death protein ligand-1 (PD-L1) and marker of proliferation Ki-67 (Ki67) in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients treated with pembrolizumab. The results showed that PD patients had higher levels of PD-L1 and Ki67 expression after the first treatment cycle, while DC patients had reduced expression levels. The study also found that PD-L1 positive patients with high Ki67 expression had shorter survival. These findings suggest that monitoring PD-L1 and Ki67 expression in CTCs may predict the efficacy of pembrolizumab.

MOLECULAR ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients

Mustafa Abdo et al.

Summary: Alternative sources of tumour information, such as cytology imprints and circulating tumour cells (CTCs), can be explored in NSCLC patients. This study compared the expression of PD-L1 on cytology imprints and CTCs to PD-L1 tumour proportion score (TPS) from immunohistochemistry staining of tumour tissue. The combination of cytological imprints and CTCs provides valuable information on the tumoural PD-L1 status in NSCLC patients when tumour tissue is not available.

MOLECULAR ONCOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Laeeq ur Rehman et al.

Summary: Prostate cancer is the most common cancer in men worldwide, accounting for 21% of all cancer cases. This systematic review analyzed completed Phase III clinical trials on immunotherapy for prostate cancer, and also compiled an index of ongoing clinical trials. Promising results were found for ipilimumab intervention, and numerous ongoing trials are expected to further improve outcomes for patients with prostate cancer.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Oncology

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact

Vasileios Vardas et al.

Summary: This study investigated the expression of PD-L1, CTLA-4, GLU, and VIM in circulating tumor cells (CTCs) of triple negative breast cancer (TNBC) patients. All the examined proteins were upregulated in TNBC patients. GLU(+)VIM(+)CK(+) phenotype was more prevalent in metastatic TNBC, and significant correlation was found between PD-L1(+)CD45(-)CK(+) and CTLA-4(+)CD45(-)CK(+) phenotypes, suggesting the importance of dual inhibition in breast cancer. Moreover, GLU(+)VIM(+)CK(+) and PD-L1(+)CD45(-)CK(+) phenotypes were associated with shorter overall survival in TNBC patients, indicating their potential as prognostic biomarkers.

CANCERS (2023)

添加到收藏夹

Review Oncology

Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities

Alexander T. Bauer et al.

Summary: Advances in understanding the molecular mechanisms of tumor progression have led to significant progress in cancer treatment, particularly with the use of immune checkpoint inhibitors (ICIs). However, response rates are still limited, and secondary resistance and severe side effects are common. This review focuses on the role of coagulation in fostering mechanisms associated with tumor progression.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis G. Paz-Ares et al.

Summary: Nivolumab plus ipilimumab continues to demonstrate durable long-term efficacy in patients with advanced NSCLC, with a significant improvement in overall survival compared to chemotherapy. Immune-mediated adverse events occur early but can be managed with guideline-based treatment. Discontinuation of nivolumab plus ipilimumab due to adverse events does not impact the long-term benefits seen in all randomized patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Surgery-mediated tumor-promoting effects on the immune microenvironment

Xiang Cheng et al.

Summary: Surgical resection remains the main treatment for solid cancers, but it can induce platelet activation and recruitment of neutrophils, promoting tumor growth and metastasis. Moreover, surgery leads to recruitment and expansion of immunosuppressive cells and suppression of natural killer cells, contributing to postoperative cancer recurrence and metastasis.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Oncology

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Paolo Tarantino et al.

Summary: Advancements in the treatment of localized triple negative breast cancer (TNBC) are reshaping the landscape of this disease, with the addition of pembrolizumab showing significant improvement in survival. However, there are still questions regarding patient selection, integration with other treatments, and minimizing side effects.

NPJ BREAST CANCER (2022)

添加到收藏夹

Article Biology

An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets

Eunice Dotse et al.

Summary: Immune modulation is a key factor in cancer, as tumor cells interact with immune cells in the process of metastasis. Circulating tumor cells (CTCs), which have disseminated from the tumor into circulation, play an important role in diagnosis, prognosis, and treatment response monitoring. It is crucial to understand the complex crosstalk between CTCs and the immune system in order to devise new diagnostic and treatment strategies.

LIFE-BASEL (2022)

添加到收藏夹

Article Oncology

Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells

Katarina Kolostova et al.

Summary: By using the CliniMACS Prodigy (R) machine and CTC lysates, we successfully generated Mo-DCs and demonstrated their potential to activate NTBC in co-cultures.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma

Matthew Bootsma et al.

Summary: In this study, liquid biopsies were used to analyze CTC enumeration and the HLA I to PD-L1 ratio in metastatic renal cell carcinoma (mRCC) patients. The results showed that changes in CTC abundance and the HP ratio were significantly associated with treatment response and overall survival. These findings provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

Sara Elena Rebuzzi et al.

Summary: This review evaluates the potential role of immunotherapy in advanced prostate cancer and discusses the immunobiology of PCa, ongoing trials, and available clinical data. It suggests that immunotherapy may be effective in certain subsets of patients and highlights the importance of further research in identifying predictive biomarkers and exploring new therapeutic targets.

CANCERS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical Applications of Cancer-Associated Cells Present in the Blood of Cancer Patients

Cha-Mei Tang et al.

Summary: The ability to obtain tumor material from blood of cancer patients has significant advantages over the use of tumor tissue, with cancer-associated macrophage-like cells (CAMLs) being more useful than traditionally defined circulating tumor cells (CTCs) in some cases.

BIOMEDICINES (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy

Zaigang Zhou et al.

Summary: The study designed and constructed MB@Bu@MnO2 nanoparticles with two-step oxygen regulation and PD-1/PD-L1 axis disruption capabilities, effectively addressing the limitations of traditional PDT.

JOURNAL OF CONTROLLED RELEASE (2022)

添加到收藏夹

Review Oncology

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

Salman R. R. Punekar et al.

Summary: Over the past decades, immunotherapy has proven its effectiveness in various cancer types. In recent years, it has emerged as a viable treatment approach for non-small cell lung cancer (NSCLC). The use of immune checkpoint blockade (ICB) with antibodies such as anti-PD-1, anti-CTLA-4, and anti-PD-L1 has shown promising results in clinical trials, improving progression-free survival and overall survival compared to chemotherapy alone. Biomarkers to predict response to immunotherapy are still being studied. The future of lung cancer immunotherapy holds potential with the development of combination therapies, cytokine modulating therapies, and cellular therapies. Additionally, advanced technologies like artificial intelligence (AI) and machine learning are expected to play a role in the future care of lung cancer patients.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

Ke Su et al.

Summary: The study demonstrates that PD-L1(+) CTCs can be used as a predictive biomarker in HCC patients receiving PD-1 inhibitors combined with IMRT and antiangiogenic therapy in order to evaluate treatment efficacy.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis

Xianmin Meng et al.

Summary: The metastasis of breast cancer is a major cause of death in patients and is closely associated with circulating tumor cells and the metastatic microenvironment. This study demonstrated the potential of SA-modified liposomes in targeting tumor-associated macrophages for enhanced drug delivery, resulting in increased cellular uptake, improved cytotoxicity, and minimal toxicity. The depletion of tumor-associated macrophages through this delivery system also regulated the tumor microenvironment.

AAPS PHARMSCITECH (2022)

添加到收藏夹

Article Oncology

Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients

Patricia Mondelo-Macia et al.

Summary: This study confirmed the prognostic value of cfDNA quantitative analysis in SCLC patients before and during therapy, and developed a new risk prognostic model that can help identify patients who could benefit from current treatments.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

Jillian A. Moran et al.

Summary: This study found that blood-based monitoring of dynamic changes in PD-L1 in TACs can identify patients with rmNSCLC who may benefit from ICI therapy.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Heather J. Chalfin et al.

Summary: This study found that in patients with metastatic genitourinary cancer, high CTC counts, specific CTC morphologic subtypes, and PD-L1(+) CTCs were associated with shorter survival. Further research is needed to validate the prognostic utility of CTC heterogeneity and detection of specific CTC morphologies.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer

Madhavi Manyam et al.

Summary: The study demonstrated promising safety, clinical activities, and immune activation of intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory ovarian cancer (PRROC), indicating the need for further clinical investigation.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

On-Chip Biogenesis of Circulating NK Cell-Derived Exosomes in Non-Small Cell Lung Cancer Exhibits Antitumoral Activity

Yoon-Tae Kang et al.

Summary: NK cells and their derived exosomes play a crucial role in cancer immunotherapy, as they exhibit high stability and lower immunogenicity, providing possibilities for personalized treatments. A novel microfluidic system for collecting patient-specific NK cells and NK-exosomes on chips offers potential applications in cancer therapies.

ADVANCED SCIENCE (2021)

添加到收藏夹

Article Oncology

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer

Tian Zhang et al.

Summary: The study found that CTCs from men with mPC often express B7-H3, and there is heterogeneity in the expression of immune checkpoints PD-L1, PD-L2, and CTLA-4 across different disease states. Detection of these immune checkpoints in CTCs may aid in monitoring immunotherapy efficacy.

BIOMARKER RESEARCH (2021)

添加到收藏夹

Article Oncology

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Filippo G. Dall'Olio et al.

Summary: This study found that PD-L1 expression on CTCs is correlated with overall survival in lung cancer patients, while CTC number is associated with baseline tumor size.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer

Maria Beatrice Morelli et al.

Summary: The study suggests that high levels of PD-L1, TWIST1 and TIMP2 mRNA may indicate recurrence in non-muscle invasive bladder cancer (NMIBC) patients and are associated with a reduced recurrence-free survival.

CANCERS (2021)

添加到收藏夹

Review Oncology

Liquid Biopsy: From Discovery to Clinical Application

Catherine Alix-Panabieres et al.

Summary: CTC and ctDNA have been recognized as promising biomarkers with various clinical applications, including early cancer detection and therapeutic monitoring. However, challenges such as standardization and validation of clinical effectiveness need to be addressed in this dynamic field of translational cancer research.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Mio Ikeda et al.

Summary: In non-small cell lung cancer patients, sequential evaluation of PD-L1 expression on CTCs can predict long-term efficacy of nivolumab treatment. Patients with PD-L1 positivity rates >= 7.7% at week 8 had significantly longer progression-free survival compared to those with <7.7%.

CANCERS (2021)

添加到收藏夹

Article Medical Laboratory Technology

Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer

Lea Sinoquet et al.

Summary: The presence of PD-L1(+) CTCs is associated with poor prognosis in patients with advanced NSCLC, showing low concordance with PD-L1 expression in tumor tissue, and further studies with larger samples are needed for confirmation.

CLINICAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab

Patricia Mondelo-Macia et al.

Summary: In this study, the value of liquid biopsy analyses, including cfDNA and CTCs, as a prognostic or predictive tool in guiding pembrolizumab therapy for NSCLC was explored. Patients with high baseline cfDNA levels had poorer progression-free survival and overall survival, while those with unfavorable changes in cfDNA levels over 12 weeks had a higher risk of disease progression. Detection of CTCs using the CellSearch(R) system was associated with shorter PFS and OS in patients. The combination of CTCs and cfDNA levels was identified as an early independent predictor of disease progression.

MOLECULAR ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies

Zhaoli Tan et al.

Summary: The study investigates the role of PD-L1 expression on circulating tumor cells in predicting and monitoring response to PD-1/PD-L1 blockade immunotherapies in advanced cancer patients. Results suggest that PD-L1-high-expression CTCs serve as a predictive biomarker and prognostic factor in patients treated with anti-PD-1/PD-L1 monoclonal antibodies, indicating its potential as a clinical biomarker for immunotherapy.

ONCOLOGIST (2021)

添加到收藏夹

Review Oncology

Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis

Yushu Ouyang et al.

Summary: Our meta-analysis found that PD-L1 positive expression on CTCs predicted better survival prognosis for ICI treatment but worse survival for other therapies. Post-treatment PD-L1(+) CTCs predicted worse PFS and OS. The prognostic value of PD-L1(+) CTCs was significantly modulated by comparison models.

CANCER MEDICINE (2021)

添加到收藏夹

Review Oncology

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy

Hirofumi Shibata et al.

Summary: The article discusses the potential of neoadjuvant immunotherapy in enhancing clinical outcomes for HNSCC, highlighting the current mainstay of treatment, limitations of induction chemotherapies, and the success of immunotherapies in recurrent and metastatic cases. It emphasizes the shift in treatment algorithm that neoadjuvant immunotherapy could bring to HNSCC.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Circulating tumor cells: biology and clinical significance

Danfeng Lin et al.

Summary: CTCs, tumor cells that have sloughed off the primary tumor and circulate in the blood, have potential for identifying targets against cancer metastasis. Detecting these rare CTCs in the massive pool of blood cells is challenging, but emerging detection technologies have deepened our understanding of their biology and clinical applications. Molecular markers, such as epithelial cell adhesion molecule, play a key role in CTC detection, with properties like epithelial-to-mesenchymal transition and stemness indicating increased metastatic capacity.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Oncology

PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

Muhammad A. Khattak et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors

Angelo Castello et al.

CANCERS (2020)

添加到收藏夹

Review Cell Biology

The roles of tumor-associated macrophages in tumor angiogenesis and metastasis

Luo-Qin Fu et al.

CELLULAR IMMUNOLOGY (2020)

添加到收藏夹

Review Immunology

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Massimo Ralli et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2020)

添加到收藏夹

Article Oncology

Prognostic impact of indoleamine 2,3-dioxygenase 1(IDO1)mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma

Panagiota Economopoulou et al.

ESMO OPEN (2020)

添加到收藏夹

Article Oncology

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)

Sonja Bergmann et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer

Yumei Yang et al.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2019)

添加到收藏夹

Review Oncology

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Massimo Cristofanilli et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Neutrophils escort circulating tumour cells to enable cell cycle progression

Barbara Maria Szczerba et al.

NATURE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

Yang Wang et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Multidisciplinary Sciences

HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study

Panagiota Economopoulou et al.

PLOS ONE (2019)

添加到收藏夹

Article Oncology

Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)

Panagiota Economopoulou et al.

ORAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Menno Tamminga et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Medicine, General & Internal

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

Angela Alama et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Oncology

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

Melanie Janning et al.

CANCERS (2019)

添加到收藏夹

Review Oncology

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?

Emmanuel Acheampong et al.

CANCERS (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy

Shu Lian et al.

ONCOTARGETS AND THERAPY (2019)

添加到收藏夹

Review Cell Biology

Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents

Carmen Garrido-Navas et al.

CELLS (2019)

添加到收藏夹

Article Medical Laboratory Technology

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma

Sabine Riethdorf et al.

CLINICAL CHEMISTRY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients

Jeffrey C. Thompson et al.

LUNG CANCER (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Shu Lian et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Oncology

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

Nicolas Guibert et al.

LUNG CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Emergencies in the Treatment of Wandering Spleen

Osher Cohen et al.

ISRAEL MEDICAL ASSOCIATION JOURNAL (2018)

添加到收藏夹

Article

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

Karim Boudadi et al.

Oncotarget (2018)

添加到收藏夹

Article Urology & Nephrology

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

Takashi Kawahara et al.

BMC UROLOGY (2018)

添加到收藏夹

Article Oncology

The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer

Arutha Kulasinghe et al.

CANCER MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

Xin Hong et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

添加到收藏夹

Article Oncology

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

M. Ilie et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer

Michal Mego et al.

ONCOTARGET (2017)

添加到收藏夹

Review Cell Biology

A conduit to metastasis: circulating tumor cell biology

Douglas S. Micalizzi et al.

GENES & DEVELOPMENT (2017)

添加到收藏夹

Article Immunology

Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer

Mao Lin et al.

IMMUNOLOGY LETTERS (2017)

添加到收藏夹

Review Oncology

Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs)

P. Economopoulou et al.

ORAL ONCOLOGY (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer

Shuzhen Liang et al.

ONCOTARGETS AND THERAPY (2017)

添加到收藏夹

Article Oncology

Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors

Dorothea Sonja Schott et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer

Zhaomei Mu et al.

BREAST CANCER RESEARCH AND TREATMENT (2017)

添加到收藏夹

Article Oncology

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma

A. Strati et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Gerhard Hamilton et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

M. Ilie et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation

Juechao Zhang et al.

TUMOR BIOLOGY (2016)

添加到收藏夹

Review Pathology

Improving the CellSearch® system

J. F. Swennenhuis et al.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)

添加到收藏夹

Article Medicine, General & Internal

Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma: A new hypothesis and a new predictor for distant metastasis

Lianyuan Tao et al.

MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

Chiara Nicolazzo et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Oncology

Frequent expression of PD-L1 on circulating breast cancer cells

Martine Mazel et al.

MOLECULAR ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer

Gunnar Steinert et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

Nicola Aceto et al.

CELL (2014)

添加到收藏夹

Review Immunology

Tumor-Associated Macrophages: From Mechanisms to Therapy

Roy Noy et al.

IMMUNITY (2014)

添加到收藏夹

Editorial Material Oncology

Macrophages in the liver prevent metastasis by efficiently eliminating circulating tumor cells after monoclonal antibody immunotherapy

Nuray Gull et al.

ONCOIMMUNOLOGY (2014)

添加到收藏夹

Review Immunology

NK cell-based immunotherapy for malignant diseases

Min Cheng et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2013)

添加到收藏夹

Article Oncology

Neutrophils Promote Liver Metastasis via Mac-1-Mediated Interactions with Circulating Tumor Cells

Jonathan D. Spicer et al.

CANCER RESEARCH (2012)

添加到收藏夹

Article Oncology

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer:: A pilot study

Alexander Stojadinovic et al.

ANNALS OF SURGICAL ONCOLOGY (2007)

添加到收藏夹

Article Medicine, General & Internal

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

M Cristofanilli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.